- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Endometriosis
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 499KB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 95KB)
Relugolix with estradiol and with norethisterone acetate – November 2024
Relugolix with Estradiol and with Norethisterone Acetate; Tablet containing relugolix 40 mg with estradiol (as hemihydrate) 1 mg and with norethisterone acetate 0.5 mg; Ryeqo®
Last updated
30 May 2025
